Bovhyaluronidaze azoximer significantly reduces exercise intolerance in patients with long-term pulmonary sequelae of COVID-19
Petrovax announced today the positive results from “Long-CoV-III-21,” a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19. Bovhyaluronidase azoximer, marketed under the brand name Longidaza, is a polymer-conjugated hyaluronidase with an extended half-life. The study drug and placebo were administered for 71 days, with an observation period extending to Day 180.
Longidaza demonstrated a statistically significant 62% reduction in the proportion of patients with exertional desaturation ...












